This is a Validated Antibody Database (VAD) review about human RAD52, based on 3 published articles (read how Labome selects the articles), using RAD52 antibody in all methods. It is aimed to help Labome visitors find the most suited RAD52 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Invitrogen
mouse monoclonal (5E11E7)
  • immunocytochemistry; human; 1:500; loading ...; fig 5c
Invitrogen RAD52 antibody (Thermo Fisher, MA5-31888) was used in immunocytochemistry on human samples at 1:500 (fig 5c). Aging (Albany NY) (2021) ncbi
Santa Cruz Biotechnology
mouse monoclonal (F-7)
  • immunocytochemistry; human; 1:500; loading ...; fig 3c
Santa Cruz Biotechnology RAD52 antibody (Santa Cruz, sc-365341) was used in immunocytochemistry on human samples at 1:500 (fig 3c). NAR Cancer (2021) ncbi
Abcam
domestic rabbit monoclonal (EPR3464(2))
  • western blot; human; fig 3a
In order to find that delta133p53 enhances reprogramming efficiency in human induced pluripotent stem, Abcam RAD52 antibody (Epitomics, 5257-1) was used in western blot on human samples (fig 3a). Sci Rep (2016) ncbi
Articles Reviewed
  1. Bloniarz D, Adamczyk Grochala J, Lewinska A, Wnuk M. The lack of functional DNMT2/TRDMT1 gene modulates cancer cell responses during drug-induced senescence. Aging (Albany NY). 2021;13:15833-15874 pubmed publisher
  2. Zhu X, Wang X, Yan W, Yang H, Xiang Y, Lv F, et al. Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response. NAR Cancer. 2021;3:zcab010 pubmed publisher
  3. Gong L, Pan X, Chen H, Rao L, Zeng Y, Hang H, et al. p53 isoform Δ133p53 promotes efficiency of induced pluripotent stem cells and ensures genomic integrity during reprogramming. Sci Rep. 2016;6:37281 pubmed publisher